Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol
Letter
[키워드] 1:1
24 hour
Administered
airway
allocation concealment
Alpha
ambient
analysed
aneurysms
Anticoagulant treatment
anticoagulation
antiplatelet
Arm
arterial
assigned
Atrial fibrillation
bleeding
bleeding event
block size
Blood
BMI
Body
Breastfeeding
breath
calculated
Cancer
clinical
clinically
Coagulopathy
Concomitant
conjunctival
Continuous
contributed
Control
control group
Controlled trial
corpus
COVID-19
COVID19
criteria
Critical
D-dimer
D-dimer level
Day
death
defined
detect
diagnostic
discharged
disease severity
dissemination
dosage
dose
effective
Efficacy and safety
element
enoxaparin
Epistaxis
EudraCT
event
events
expected
fibrinogen level
gingival bleeding
group
Haemoglobin
haemoptysis
health-care
hematemesis
hematoma
hemodynamic
heparin
High dose
high risk
history
hospital discharge
Hospital stay
hospitalized patient
hypersensitivity
Hypothesis
IL-6
Impaired
impairing
improvement
IMV
In-hospital
indication
initiated
Inpatient
INR
internal
Intervention
intervention group
Intra-articular
intramuscular
invasive
Invasive mechanical ventilation
involved
Italian
Italy
laboratory parameter
LMWH
low dose
low-molecular weight heparin
macroscopic
Major
major bleeding
management
Mechanical
mechanical ventilation
medical intervention
Medicine
Modena
NIV
Non-invasive
number
objective
occur
Occurrence
open label
ophthalmic
oral anticoagulant
outcome
oxygen
paO2/fiO2
parallel group
participant
pathology
Patient
performed
Pharyngeal swab
plasma
Platelet
Pneumonia
positive
pregnancy test
Presence
pressure
Primary outcome
prophylactic dose
prosthetic
protocol
random
randomisation
randomised
randomised controlled
randomised controlled trial
randomization
Rate
receiving
recorded
recruited
Rectal Bleeding
reduce
reduction in
Registered
renal function
reported
required
respiratory
risk
risk of death
Sample size
SARS-CoV-2
secondary
secure
Severe COVID-19 pneumonia
severe disease
significantly
Spontaneous
standard oxygen therapy
Stata
status
stratified
stroke
study drug
Study protocol
subcutaneously
surgical
susceptible
symptomatic
syndrome
therapeutic dose
therapy
thrombocytopenia
time
transfusion
Treatment
unfractionated heparin
unit
Vascular
venipuncture
Venous Thromboembolism
web-based system
website
weight
Withdrawal
worsening
[DOI] 10.1186/s13063-020-04475-z PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04475-z PMC 바로가기 [Article Type] Letter